New interest in an old market: South Korea - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

New interest in an old market: South Korea
With so much attention being focused on China and India, it is possible to forget the other emerging markets in Asia...


Pharmaceutical Technology Europe



Faiz Kermani
The last decade has seen considerable investment in South Korea, and the country now represents the world's 11th largest economy and has the 11th largest GDP.1 With a population of approximately 50 million and a GDP of $14000 (€8880) per head, it is an important consumer base that international companies cannot afford to ignore.

Unfortunately, external enthusiasm for the South Korean market was severely dented by the 1997 financial crisis, which led to many foreign investors selling their assets. Since then, the country has introduced major policy changes that have made it stronger and more focused than other Asian competitors; for example, South Korea's foreign-exchange reserves have been described as the second highest after Japan among the 30 international member countries that make up the Organization for Economic Co-operation and Development. This makes the likelihood of another financial crisis reminiscent of 1997 unlikely.

As the country's economy has rebounded, so too has foreign interest. This was highlighted by the decision to hold the 2006 International Conference on Pharmaceutical Medicine (ICPM) in Seoul, South Korea's capital?— the first ICPM meeting to have been held in the Asian region.2

Driving foreign interest


The author says...
The South Korean government has invested in infrastructure and improved funding for the healthcare system to alleviate uncertainties caused by the 1997 financial crisis, and to attract the attention of the global pharmaceutical sector. The National Health Insurance (NHI) Act, introduced in 1999, integrated multiple insurance societies into a single insurer system to enhance the equity of financing for healthcare. Backed by temporary measures through the 2002 Special Act for Financial Stabilization of National Health Insurance, the government attempted to provide comprehensive healthcare services to the public. The NHI system, overseen by the Ministry of Health and Welfare,3 is mandatory for Koreans living in the country, except for some medical aid beneficiaries. In October 2003, it was estimated that the NHI Programme covered 97% of the population. The Medical Aid Programme, a Korean social assistance programme, covered the remaining 3%.

The new system has created considerable opportunities for foreign companies as there is strong demand from the population for new medicines. At present, pharmaceuticals account for approximately 30% of healthcare expenditure in South Korea.1 Estimates of the value of the country's pharmaceutical market vary, but Business Monitor International has predicted that it will reach $21.6 billion (€13.7 billion) by 2011.4

A major attraction for pharmaceutical companies is the separation of medical prescribing and dispensing, which was a key reform of the South Korean healthcare system in July 2000. This process marked a shift from dispensing doctors to a retail pharmacy market and was strongly resisted by physicians, who had traditionally derived a large proportion of their income from pharmaceuticals.

These measures appear to have benefited multinational pharmaceutical companies, which are dominating the market,1 and South Korean consumers are now more aware of branded medications. As foreign companies tend to introduce the latest breakthrough medicines, they have had the most success. In contrast, many local companies have become so reliant on income streams from the government for generic drugs that they have little desire to innovate.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
42%
No government involvement in patient treatment or drug development.
12%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology Europe,
Click here